TGF-β signaling in tumor suppression and cancer progression
R Derynck, RJ Akhurst, A Balmain - Nature genetics, 2001 - nature.com
Epithelial and hematopoietic cells have a high turnover and their progenitor cells divide
continuously, making them prime targets for genetic and epigenetic changes that lead to cell …
continuously, making them prime targets for genetic and epigenetic changes that lead to cell …
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
F Chang, LS Steelman, JT Lee… - Leukemia …, 2003 - search.ebscohost.com
Abstract The Ras/Raf/Mitogen-activated protein kinase/ERK kinase (MEK)/extracellular-
signal-regulated kinase (ERK) cascade couples signals from cell surface receptors to …
signal-regulated kinase (ERK) cascade couples signals from cell surface receptors to …
Histone deacetylases: unique players in shaping the epigenetic histone code
The epigenome is defined by DNA methylation patterns and the associated posttranslational
modifications of histones. This histone code determines the expression status of individual …
modifications of histones. This histone code determines the expression status of individual …
TGF-β signaling: positive and negative effects on tumorigenesis
LM Wakefield, AB Roberts - Current opinion in genetics & development, 2002 - Elsevier
TGF-β binding to the cell surface triggers activation of multiple signal transduction pathways
that are connected in intricate ways with each other, and with other response networks …
that are connected in intricate ways with each other, and with other response networks …
Clinical development of histone deacetylase inhibitors as anticancer agents
DC Drummond, CO Noble, DB Kirpotin… - Annu. Rev …, 2005 - annualreviews.org
▪ Abstract Acetylation is a key posttranslational modification of many proteins responsible for
regulating critical intracellular pathways. Although histones are the most thoroughly studied …
regulating critical intracellular pathways. Although histones are the most thoroughly studied …
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non–small
cell lung cancers (NSCLC). EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib …
cell lung cancers (NSCLC). EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib …
Regulation of TGF-β receptor activity
F Huang, YG Chen - Cell & bioscience, 2012 - Springer
TGF-β signaling regulates diverse cellular processes, including cell proliferation,
differentiation, apoptosis, cell plasticity and migration. Its dysfunctions can result in various …
differentiation, apoptosis, cell plasticity and migration. Its dysfunctions can result in various …
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen …
RR Rosato, JA Almenara, S Grant - Cancer research, 2003 - AACR
Abstract Effects of the histone deacetylase (HDAC) inhibitor MS-275 have been examined in
human leukemia and lymphoma cells (U937, HL-60, K562, and Jurkat) as well as in primary …
human leukemia and lymphoma cells (U937, HL-60, K562, and Jurkat) as well as in primary …
TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression
B Tang, M Vu, T Booker, SJ Santner… - The Journal of …, 2003 - Am Soc Clin Investig
The TGF-β signaling network plays a complex role in carcinogenesis because it has the
potential to act as either a tumor suppressor or a pro-oncogenic pathway. Currently, it is not …
potential to act as either a tumor suppressor or a pro-oncogenic pathway. Currently, it is not …
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
QC Ryan, D Headlee, M Acharya… - Journal of Clinical …, 2005 - ascopubs.org
Purpose The objective of this study was to define the maximum-tolerated dose (MTD), the
recommended phase II dose, the dose-limiting toxicity, and determine the pharmacokinetic …
recommended phase II dose, the dose-limiting toxicity, and determine the pharmacokinetic …